Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.00−0.24 (-1.81%)
Close on Nov 20, 2026Market cap $861.89MP/E –Yield 0.00%
Latigo Biotherapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Latigo Biotherapeutics
Latigo Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?